Business
Update from iSCIB1+ Clinical Advisory Meeting
Update from iSCIB1+ Clinical Advisory Meeting.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n24 July 2024\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nScancell Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial\n \nA panel of international key opinion leaders in the treatment of Melanoma convened in Chicago to offer strategic guidance in the design of Scancell's Phase 2/3 seamless adaptive registration study.\n \nThe SCIB1 stage 1 clinical data poster was very well received at ASCO.\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that a group of leading medical oncologists in the field of melanoma treatment reviewed and strengthened Scancell's plan for a Phase 2/3 registration study following completion of the ongoing SCOPE study.\n \nScancell's plans to conduct an adaptive randomised controlled Phase 2/3 SCOPE-2 trial is supported by a panel of experts. The study is expected to have an early interim analysis of Overall Response Rate (ORR) based on a blinded independent centralised review of CT/MRI scans before advancing to the Phase 3 component where the primary endpoint of progression-free survival will be analysed at a predetermined landmark. \n \nThe panel comprised the following members:\n \n\n\n\n\nName\n\n\nInstitution\n\n\n\n\nPaul Chapman\n\n\nWeill Cornell Medicine and NewYork-Presbyterian, New York, NY, USA\n\n\n\n\nPippa Corrie\n\n\nCambridge Cancer Centre, Addenbrooke's Hospital, Cambridge, UK\n\n\n\n\nAlexander Eggermont\n\n\nPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.\n\n\n\n\nGeorgina Long\n\n\nMelanoma Institute Australia, Sydney, Australia.\n\n\n\n\nSapna Patel\n\n\nUniversity of Colorado Cancer Center, USA\n\n\n\n\nMichael Postow\n\n\nMemorial Sloan Kettering Cancer Center, New York, NY, USA\n\n\n\n\nHeather Shaw\n\n\nUniversity College Hospital, London, UK\n\n\n\n\nJeffrey Weber\n\n\nPelmutter Cancer Center, New York, NY, USA\n\n\n\n\nJedd Wolchok\n\n\nWeill Cornell Medicine and NewYork-Presbyterian, New York, NY, USA\n\n\n\n\n \nA poster, presenting the first stage of the SCOPE study, was also very well received at ASCO with Prof Durrant, Dr Heather Shaw, Dr Robert Miller and Mr Fayaz Master discussing the results for three hours with oncologists, pha...